



Water soluble. Easily absorbed
World-leading polyphenols for precision health

RenoCidin™

600% | Most bioavailable hesperetin
Exercise performance and metabolic wellness

- 10,000X Aqueous solubility
- 6X Superior bioavailability
- Clinical proven efficacy
- International innovation gold awards
- US FDA New Dietary Ingredient (1253)



High solubility
High bioavailability




Small molecule
Fast absorption



Efficient delivery
Maximum efficacy

RenoCidin™ — a breakthrough fermented citrus polyphenol powered by RenoSorb™ postbiotic exo-delivery technology. Standardized with highly water-soluble hesperetin phosphate, it ensures superior absorption and efficacy, unleashing nature's restorative power. As a Cisd2 longevity activator, RenoCidin™ promotes healthy aging, enhances metabolic wellness and exercise performance, supports vascular health, and helps maintain fluid balance.



Hesperetin phosphate

RenoCidin™

Most bioavailable hesperetin
Exercise performance and metabolic wellness



EXERCISE
BOOST



CIRCULATION
HEALTH




METABOLIC
WELLNESS



EYE
HEALTH


RenoSorb™ Technology platform

Next Generation pharma-grade postbiotics exo-precursor delivery technology



Pharmacokinetic profile

6x better absorption



Mean plasma concentration-time profiles of hesperetin in rats after oral administration of native hesperetin and RenoCidin™ at 22.8 μmol/kg bw. Data are mean ± SE (n = 4).

Journal of Agricultural and Food Chemistry 69.35 (2021): 10184-10193.




Vitafoods Europe
2023 Startup Innovation Challenge Award
Finalist


2025 Gold Award Winner, Taipei Biotech Awards — The Biotech Oscars “Innovative Technology Award (Applied Biotechnology)”

2023 Top 5 Global Finalist, Vitafoods Europe Startup Challenge Award “Most Innovative Technology Supporting the Nutraceutical Industry”

Clinical study Improve exercise performance




Randomized, double-blind, placebo-control clinical study. 32 healthy subjects (18-40 years old) were tested for the effect of an 8-week RenoCidin™ trial on biochemical changes after EIMD. Results are mean ± SEM (n = 16). Different superscript letters and * indicate significant differences (p < 0.05). Unpublished data



Clinical study Metabolic wellness

Randomized, double-blind, placebo-control Clinical Study. 32 borderline hyperlipidemia subjects (aged 18-40, TC ~200 mg/dL) were enrolled into placebo or RenoCidin™ groups for an 8-week trial to evaluate the effect of RenoCidin™ on blood lipid and blood glucose regulation. *p < 0.05, **p < 0.01, ***p < 0.001. Mean ± SEM. Unpublished data



Animal study Cardiovascular & circulation health

Blood circulation effect of fermented citrus bioconversion product (FCBP) in EA.hy926 endothelial cells and high-fat diet-fed mouse model.

Food & Nutrition Research 2024, 68: 10682

Recommended dose: 100-200 mg



Hughes Biotechnology Co., Ltd.

ADD 12F.-2, No.420, Sec.1, Keelung Rd., Xinyi Dist., Taipei City 110, Taiwan

TEL +886-2-2758-2232

WEB <http://www.hughesbiotech.com/>

MAIL service@hughesbiotech.com

